Galderma, a company specializing in aesthetic treatments such as botulinum toxin (commonly known as botox), facial fillers, and collagen stimulators, has reported a significant boost in its aesthetics portfolio, driven by the rising use of GLP-1 medications for weight loss in the United States. CEO Flemming Ørnskov stated that about 10% of U.S. adults now report taking GLP-1 drugs like Ozempic, Wegovy, or Zepbound for weight loss, which is fueling increased demand for treatments addressing facial volume loss, a phenomenon sometimes referred to as 'Ozempic face' [1].
Ørnskov highlighted that Galderma was the first to demonstrate that using two of its products—filler and Sculptra—can mitigate some of the facial sagging associated with significant weight loss. He described the trend as a 'significant opportunity' for the company, though he noted that it is still in the early stages [1].
Financially, Galderma reported nearly 25% year-on-year sales growth at constant currencies, with U.S. growth outpacing the rest of the world at 32% compared to 19% elsewhere. The U.S. remains the largest market for GLP-1 drugs and is driving the company's strong performance in aesthetics [1].
Despite these positive results, the Swiss-listed stock was little moved in mid-morning trading, indicating a muted immediate market reaction [1].
CONCLUSION
Galderma is experiencing robust sales growth, particularly in the U.S., as the popularity of GLP-1 weight-loss drugs increases demand for aesthetic treatments. While the company sees this as a significant long-term opportunity, the market response to the latest results has been relatively subdued.